Blocking Previously ‘Undruggable’ Cancer Protein
News Apr 13, 2015
A team of scientists at the University of Kansas has pinpointed six chemical compounds that thwart HuR, an ‘oncoprotein’ that binds to RNA and promotes tumor growth.
The findings, which could lead to a new class of cancer drugs, appear in the current issue of ACS Chemical Biology.
“These are the first reported small-molecule HuR inhibitors that competitively disrupt HuR-RNA binding and release the RNA, thus blocking HuR function as a tumor-promoting protein,” said Liang Xu, associate professor of molecular biosciences and corresponding author of the paper.
The results hold promise for treating a broad array of cancers in people. The researcher said HuR has been detected at high levels in almost every type of cancer tested, including cancers of the colon, prostate, breast, brain, ovaries, pancreas and lung.
“HuR inhibitors may be useful for many types of cancer,” Xu said. “Since HuR is involved in many stem cell pathways, we expect HuR inhibitors will be active in inhibiting ‘cancer stem cells,’ or the seeds of cancer, which have been a current focus in the cancer drug discovery field.”
HuR has been studied for many years, but until now no direct HuR inhibitors have been discovered, according to Xu.
“The initial compounds reported in this paper can be further optimized and developed as a whole new class of cancer therapy, especially for cancer stem cells,” he said. “The success of our study provides a first proof-of-principle that HuR is druggable, which opens a new door for cancer drug discovery. Many other RNA-binding proteins like HuR, which are so far undruggable, can also be tested for drug discovery using our strategy.”
The research team evaluated about 6,000 compounds from both the KU Chemical Methodologies and Library Development Center and the Food and Drug Administration in a process known as “High Throughput Screening,” hunting for compounds that obstruct HuR’s interface with healthy human RNA.
The KU researchers confirmed the potential of the most promising compounds with cutting-edge techniques like Amplified Luminescent Proximity Homogeneous Assay, surface plasmon resonance, ribonucleoprotein immunoprecipitation assay and luciferase reporter functional studies — verifying that six compounds with a similar “scaffold” could be starting points of novel cancer drugs to target the oncoprotein HuR.
“A cancer-causing gene, or oncogene, makes RNA, which then makes an oncoprotein that causes cancer or makes cancer cells hard to kill, or both,” Xu said. “This is the problem we’re trying to overcome with precision medicine.”
The scientist said the HuR-RNA binding site is like a long, narrow groove, not a well-defined pocket seen in other druggable proteins targeted by many current cancer therapies.
“HuR tightly binds to RNA like a hand,” Xu said. “The HuR protein grabs the ‘rope’ — or the RNA — at a site called ‘ARE’ on the rope. We aimed to find a small-molecule compound that makes the hand release the rope by competing with ARE of the RNA.”
The research took more than 3 1/2 years and involved the collaboration of chemists, cancer biologists, computer modeling experts, biochemists and biophysicists at KU — notably the labs of Xu, Jeffrey Aubé in the Department of Medicinal Chemistry and Jon Tunge in the Department of Chemistry.
Grants from the National Institutes of Health, along with funding from the state of Kansas, the Hall Family Foundation and Bold Aspiration funding from KU’s Office of the Provost, supported the work.
For Xu, the findings are reflective of a personal commitment to improving odds for people diagnosed with cancer, the second-largest killer in the U.S. after heart disease.
“Trained as medical doctor and Ph.D., with both a grandfather and an uncle who died of cancer, I devoted my career to cancer research and drug discovery — aiming to translate discovery in the lab into clinical therapy, to help cancer patients and their families,” he said. “We hope to find a better therapy — and eventually a cure — for cancer.”
Collaborators from KU and KU Medical Center include Xiaoqing Wu, Lan Lan, David Michael Wilson, Rebecca Marquez, Wei-chung Tsao, Philip Gao, Anuradha Roy, Benjamin Andrew Turner, Peter McDonald, Jon Tunge, Steven Rogers, Dan Dixon and Jeffrey Aubé.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018